【INN】Bevacizumab, biosimilar of Avastion

【Indication】Non-small cell lung cancer

【Protein Type】Monoclonal antibody

【Mechanism of Action】

Bevacizumab acts by selectively binding circulating VEGF, thereby inhibiting the binding of VEGF to its cell surface receptors. This inhibition leads to a reduction in microvascular growth of tumor blood vessels and thus limits the blood supply to tumor tissues. These effects also lower tissue interstitial pressure, increase vascular permeability, may increase delivery of chemotherapeutic agents, and favor apoptosis of tumor endothelial cells